Peter Lamb - Oct 15, 2021 Form 4 Insider Report for EXELIXIS, INC. (EXEL)

Role
EVP, Scientific Strategy & CSO
Signature
/s/ Jennifer Drimmer Rokovich, Attorney in Fact
Stock symbol
EXEL
Transactions as of
Oct 15, 2021
Transactions value $
-$746,225
Form type
4
Date filed
10/15/2021, 08:15 PM
Previous filing
Oct 4, 2021
Next filing
Nov 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXEL Common Stock Options Exercise $295K +47.5K +11.55% $6.21 459K Oct 15, 2021 Direct F1
transaction EXEL Common Stock Sale -$1.04M -47.5K -10.35% $21.92 411K Oct 15, 2021 Direct F2, F3
holding EXEL Common Stock 17.1K Oct 15, 2021 By 401(k) F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXEL Option (right to buy) Options Exercise $0 -47.5K -33.33% $0.00 95K Oct 15, 2021 Common Stock 47.5K $6.21 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 229,577 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2021.
F3 Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.69 to $22.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4 Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of October 14, 2021.
F5 The option, representing the right to purchase a total of 190,000 shares of Exelixis, Inc. common stock, became fully exercisable on September 16, 2019.